<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02919293</url>
  </required_header>
  <id_info>
    <org_study_id>085201602</org_study_id>
    <nct_id>NCT02919293</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age</brief_title>
  <official_title>Immunogenicity and Safety of Adjuvant and Adjuvant-Free Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Center for Disease Prevention and Control</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gaozhou Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes for Food and Drug Control, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Simoon Record Pharma Information Consulting Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate Immunogenicity and Safety of Adjuvant and Adjuvant-Free Meningococcal Groups A
      and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age.

      Primary objective:

        -  To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups
           A, C and Haemophilus influenzae type b following the administration of adjuvant-free
           MenAC-Hib conjugate vaccine compared to those observed following the administration of
           adjuvant MenAC-Hib conjugate vaccine.

        -  To describe the safety profile of adjuvant-free MenAC-Hib conjugate vaccine compared to
           that of adjuvant MenAC-Hib conjugate vaccine.

      Secondary objective:

      •To compare the antibody level of meningococcal serogroups A, C and Haemophilus influenzae
      type b following the administration of adjuvant-free MenAC-Hib conjugate vaccine to those
      observed following the administration of adjuvant MenAC-Hib conjugate vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with seroresponse to meningococcal serogroups A,C and Haemophilus b post-vaccination with 3 doses of MenAC-Hib conjugate vaccine</measure>
    <time_frame>Day 30 post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse events during a 30 day follow-up period after each vaccination</measure>
    <time_frame>30 day after each vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of severe adverse events within six months post-vaccination</measure>
    <time_frame>six months post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer （GMT）of antibodies against meningococcal serogroups A, C and Haemophilus b post-vaccination with 3 doses of MenAC-Hib conjugate vaccine</measure>
    <time_frame>Day 30 post-vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Meningitis</condition>
  <condition>Meningococcal Meningitis</condition>
  <condition>Meningococcal Infections</condition>
  <arm_group>
    <arm_group_label>Adjuvant-Free MenAC-Hib Conjugate Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive adjuvant-free MenAC-Hib conjugate vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant MenAC-Hib Conjugate Vaccine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to receive adjuvant MenAC-Hib conjugate vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)</intervention_name>
    <description>30μg /dose, Intramuscular</description>
    <arm_group_label>Adjuvant-Free MenAC-Hib Conjugate Vaccine Group</arm_group_label>
    <other_name>HibACon</other_name>
    <other_name>MenAC-Hib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)</intervention_name>
    <description>0.5ml /dose, Intramuscular</description>
    <arm_group_label>Adjuvant MenAC-Hib Conjugate Vaccine Group</arm_group_label>
    <other_name>HibACon</other_name>
    <other_name>MenAC-Hib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Health infants aged 2 to 5 months.

          -  Legal guardian has signed written informed consent.

          -  Guardian may finish the whole visit in the judgment of investigator.

          -  2-5 months health infants who haven't immuned with any Meningococcal A and C Conjugate
             Vaccine or Haemophilus b Conjugate Vaccine.

          -  Subject who did't vaccinated with any live vaccine within 14 days or inactivated
             vaccine within 10 days before vaccination.

        Exclusion Criteria:

          -  Fever, body temperature ≥37.1℃.

          -  History of severe allergic reaction that needs medical intervention including throat
             swelling, dyspnea, hypotension or shock; History of allergic reaction to vaccine or to
             any of the vaccine components especially to tetanus toxoid or history of other severe
             adverse reaction to vaccine.

          -  Clear diagnosis of thrombocytopenia or history of other coagulation disorders that may
             cause contraindications of intramuscular injection.

          -  Subject with history of abnormal labor, asphyxia rescue history,congenital
             malformations,eccyliosis or severe chronic disease.

          -  Severe cardiovascular or liver and kidney disease, active tuberculosis and HIV
             infection.

          -  Subject with encephalopathy, uncontrolled epilepsy and other progressive nervous
             system disease.

          -  Subject suffer from acute disease, severe chronic disease, acute episode of chronic
             disease and febrile illness (temperature ≥ 38°C) within 3 days.

          -  Any condition that, in the judgment of investigator, subject is not suitable for
             participation in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>5 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Du lin, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zeng peiyu, Bachelor</last_name>
    <phone>86-668-6578613</phone>
    <email>gzcdc6578613@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gaozhou Center for Disease Control and Prevention</name>
      <address>
        <city>Gaozhou</city>
        <state>Guangdong</state>
        <zip>525200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeng peiyu, Bachelor</last_name>
      <phone>86-668-6578613</phone>
      <email>gzcdc6578613@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2016</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

